HiFiBiO provides proprietary single cell technologies for applications in drug and biomarker discovery and development.
HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders.The company was founded in 2013 and is headquartered in Paris, Ille-de-France.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 14, 2021 | Series D | $75M | 2 | — | — | Detail |
Aug 28, 2019 | Series C | $67M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hong Kong Science and Technology Parks Corporation (HKSTP) | — | Series D |
Further | — | Series D |
Kite Pharma | — | Series C |
VI Ventures | — | Series C |